vs
Side-by-side financial comparison of IZEA Worldwide, Inc. (IZEA) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $6.1M, roughly 1.5× IZEA Worldwide, Inc.). IZEA Worldwide, Inc. runs the higher net margin — -19.3% vs -60.3%, a 41.1% gap on every dollar of revenue. On growth, IZEA Worldwide, Inc. posted the faster year-over-year revenue change (-44.9% vs -49.9%). Over the past eight quarters, IZEA Worldwide, Inc.'s revenue compounded faster (-6.6% CAGR vs -6.7%).
IZEA Worldwide, Inc. is a global marketing technology firm that operates platforms linking brands, advertising agencies, and content creators including social media influencers, bloggers, and video creators. It offers end-to-end solutions for influencer marketing campaigns, content creation, performance tracking, and audience engagement, serving clients across consumer goods, retail, technology, and entertainment sectors primarily in North America, Europe, and Asia-Pacific markets.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
IZEA vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $6.1M | $9.1M |
| Net Profit | $-1.2M | $-5.5M |
| Gross Margin | 45.8% | 49.4% |
| Operating Margin | -26.6% | -51.1% |
| Net Margin | -19.3% | -60.3% |
| Revenue YoY | -44.9% | -49.9% |
| Net Profit YoY | 74.7% | -184.8% |
| EPS (diluted) | $-0.07 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $6.1M | $9.1M | ||
| Q3 25 | $8.1M | $17.9M | ||
| Q2 25 | $9.1M | $15.7M | ||
| Q1 25 | $8.0M | $10.1M | ||
| Q4 24 | $11.0M | $18.2M | ||
| Q3 24 | $8.8M | $18.0M | ||
| Q2 24 | $9.1M | $13.5M | ||
| Q1 24 | $7.0M | — |
| Q4 25 | $-1.2M | $-5.5M | ||
| Q3 25 | $147.7K | $2.4M | ||
| Q2 25 | $1.2M | $164.0K | ||
| Q1 25 | $-142.8K | $-3.6M | ||
| Q4 24 | $-4.6M | $6.5M | ||
| Q3 24 | $-8.8M | $3.2M | ||
| Q2 24 | $-2.2M | $-2.2M | ||
| Q1 24 | $-3.3M | — |
| Q4 25 | 45.8% | 49.4% | ||
| Q3 25 | 48.6% | 53.4% | ||
| Q2 25 | 52.0% | 62.5% | ||
| Q1 25 | 44.8% | 19.1% | ||
| Q4 24 | 37.8% | 78.7% | ||
| Q3 24 | 41.0% | 53.4% | ||
| Q2 24 | 43.1% | 29.8% | ||
| Q1 24 | 42.9% | — |
| Q4 25 | -26.6% | -51.1% | ||
| Q3 25 | -4.1% | 11.9% | ||
| Q2 25 | 8.1% | 7.5% | ||
| Q1 25 | -8.2% | -41.0% | ||
| Q4 24 | -28.9% | 39.6% | ||
| Q3 24 | -105.9% | 22.2% | ||
| Q2 24 | -31.8% | -18.0% | ||
| Q1 24 | -58.4% | — |
| Q4 25 | -19.3% | -60.3% | ||
| Q3 25 | 1.8% | 13.2% | ||
| Q2 25 | 13.2% | 1.0% | ||
| Q1 25 | -1.8% | -35.8% | ||
| Q4 24 | -42.0% | 35.6% | ||
| Q3 24 | -99.3% | 18.0% | ||
| Q2 24 | -24.1% | -16.4% | ||
| Q1 24 | -47.0% | — |
| Q4 25 | $-0.07 | $-0.06 | ||
| Q3 25 | $0.01 | $0.03 | ||
| Q2 25 | $0.07 | $0.00 | ||
| Q1 25 | $-0.01 | $-0.05 | ||
| Q4 24 | $-0.25 | $0.10 | ||
| Q3 24 | $-0.52 | $0.03 | ||
| Q2 24 | $-0.13 | $-0.03 | ||
| Q1 24 | $-0.20 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $50.9M | $14.7M |
| Total DebtLower is stronger | $9.1K | — |
| Stockholders' EquityBook value | $48.9M | $48.2M |
| Total Assets | $57.5M | $82.3M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $50.9M | $14.7M | ||
| Q3 25 | $51.4M | $13.6M | ||
| Q2 25 | $50.6M | $17.9M | ||
| Q1 25 | $52.2M | $19.5M | ||
| Q4 24 | $51.1M | $19.8M | ||
| Q3 24 | $54.4M | $27.4M | ||
| Q2 24 | $55.6M | $23.4M | ||
| Q1 24 | $56.1M | — |
| Q4 25 | $9.1K | — | ||
| Q3 25 | $18.9K | — | ||
| Q2 25 | $33.7K | — | ||
| Q1 25 | $48.6K | — | ||
| Q4 24 | $63.4K | — | ||
| Q3 24 | $78.3K | — | ||
| Q2 24 | $93.1K | — | ||
| Q1 24 | $108.0K | — |
| Q4 25 | $48.9M | $48.2M | ||
| Q3 25 | $49.9M | $52.9M | ||
| Q2 25 | $49.4M | $49.9M | ||
| Q1 25 | $48.3M | $45.2M | ||
| Q4 24 | $48.8M | $43.2M | ||
| Q3 24 | $53.3M | $32.4M | ||
| Q2 24 | $60.8M | $28.6M | ||
| Q1 24 | $62.5M | — |
| Q4 25 | $57.5M | $82.3M | ||
| Q3 25 | $57.9M | $82.3M | ||
| Q2 25 | $59.6M | $78.5M | ||
| Q1 25 | $59.3M | $73.9M | ||
| Q4 24 | $62.2M | $73.4M | ||
| Q3 24 | $68.1M | $61.6M | ||
| Q2 24 | $72.7M | $91.5M | ||
| Q1 24 | $76.0M | — |
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | 0.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.2K | $2.0M |
| Free Cash FlowOCF − Capex | — | $1.6M |
| FCF MarginFCF / Revenue | — | 17.8% |
| Capex IntensityCapex / Revenue | — | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.2K | $2.0M | ||
| Q3 25 | $1.2M | $-3.7M | ||
| Q2 25 | $-762.1K | $-5.2M | ||
| Q1 25 | $2.0M | $-5.1M | ||
| Q4 24 | $-2.8M | $4.0M | ||
| Q3 24 | $-1.4M | $4.1M | ||
| Q2 24 | $-3.9M | $-3.6M | ||
| Q1 24 | $-3.3M | — |
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | $-787.8K | $-5.7M | ||
| Q1 25 | $2.0M | $-5.4M | ||
| Q4 24 | $-2.8M | $3.6M | ||
| Q3 24 | $-1.4M | $4.0M | ||
| Q2 24 | $-3.9M | $-3.8M | ||
| Q1 24 | $-3.4M | — |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | -8.6% | -36.2% | ||
| Q1 25 | 25.2% | -53.0% | ||
| Q4 24 | -25.6% | 19.6% | ||
| Q3 24 | -16.2% | 22.4% | ||
| Q2 24 | -43.2% | -28.1% | ||
| Q1 24 | -48.3% | — |
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | 0.3% | 2.8% | ||
| Q1 25 | 0.1% | 3.0% | ||
| Q4 24 | 0.2% | 2.3% | ||
| Q3 24 | 0.3% | 0.5% | ||
| Q2 24 | 0.2% | 1.3% | ||
| Q1 24 | 0.2% | — |
| Q4 25 | — | — | ||
| Q3 25 | 8.05× | -1.58× | ||
| Q2 25 | -0.63× | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IZEA
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
